ProQR (PRQR) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
ProQR Therapeutics N.V. has entered into an underwriting agreement to sell 18 million ordinary shares with the option for underwriters to purchase an additional 2.7 million shares. This public offering is facilitated by representatives from Evercore Group L.L.C. and Cantor Fitzgerald & Co., signaling a significant move in the market for investors interested in the biotech sector.
For further insights into PRQR stock, check out TipRanks’ Stock Analysis page.